What is Erste Group Bank’s Estimate for BSX FY2026 Earnings?

Boston Scientific Corporation (NYSE:BSX) – Research analysts at Erste Group Bank lowered their FY2026 earnings estimates for Boston Scientific in a report released on Friday, June 5th. Erste Group Bank analyst H. Engel now anticipates that the medical equipment provider will post earnings of $3.37 per share for the year, down from their previous forecast of $3.38. The consensus estimate for Boston Scientific’s current full-year earnings is $3.36 per share. Erste Group Bank also issued estimates for Boston Scientific’s FY2027 earnings at $3.72 EPS.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter last year, the firm earned $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS.

A number of other equities research analysts have also recently commented on the company. Wells Fargo & Company reissued an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Bank of America cut their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.92.

Boston Scientific Stock Down 1.1%

BSX stock opened at $48.42 on Thursday. The business has a 50 day moving average of $56.99 and a 200 day moving average of $75.49. The firm has a market cap of $71.98 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. Boston Scientific has a twelve month low of $47.17 and a twelve month high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock valued at $554,012 over the last ninety days. Insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp increased its position in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors increased its position in shares of Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank bought a new position in shares of Boston Scientific in the 4th quarter worth approximately $2,199,395,000. Finally, Morgan Stanley boosted its holdings in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.